Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ESMO 2016

7 - 11 Oct 2016

Bella Center, Copenhagen, Denmark

What does the Association of European Cancer Leagues (ECL) do?

Dr Wendy Yared - Director, Association of European Cancer Leagues (ECL)

What does the Association of European Cancer Leagues (ECL) do? ( Dr Wendy Yared - Director, Association of European Cancer Leagues (ECL) )

Coming of age for CDK 4/6 inhibitors: Welcome and interactive session

Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy

Coming of age for CDK 4/6 inhibitors: Welcome and interactive session ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )

What are CDKs?

Dr Ghadeer Shubassi - FIRC Institute of Molecular Oncology (IFOM), Milan, Italy

What are CDKs? ( Dr Ghadeer Shubassi - FIRC Institute of Molecular Oncology (IFOM), Milan, Italy )

CDK clinical trial results, benefit, side effects and costs

Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy

CDK clinical trial results, benefit, side effects and costs ( Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy )

Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting

Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA

Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting ( Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA )

Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers

Dr Sibylle Loibl - German Breast Cancer Group

Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers ( Dr Sibylle Loibl - German Breast Cancer Group )

Coming of age for CDK 4/6 inhibitors: Interactive session and close

Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy

Coming of age for CDK 4/6 inhibitors: Interactive session and close ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )

Biomarkers of sensitivity and resistance

Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Biomarkers of sensitivity and resistance ( Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Editor's ESMO 2016 roundup

Prof Gordon McVie - Editor in Chief, ecancer

Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )

Abiraterone in patients with recurrent epithelial ovarian cancer

Dr Susanna Banerjee - The Royal Marsden, London, UK

Abiraterone in patients with recurrent epithelial ovarian cancer ( Dr Susanna Banerjee - The Royal Marsden, London, UK )

Fatigue in men with castration resistant prostate cancer treated with enzalutamide

Dr Simon Chowdhury - Guy's Hospital, London, UK

Fatigue in men with castration resistant prostate cancer treated with enzalutamide ( Dr Simon Chowdhury - Guy's Hospital, London, UK )

PDL-1 assay concordance

Dr Jill Walker - AstraZeneca, UK

PDL-1 assay concordance ( Dr Jill Walker - AstraZeneca, UK )

CDK4/6 inhibition: PALOMA2 versus MONALEESA2

Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

CDK4/6 inhibition: PALOMA2 versus MONALEESA2 ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )

First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer

Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA

First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer ( Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA )

CDK4/6 inhibitors for metastatic breast cancer

Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

CDK4/6 inhibitors for metastatic breast cancer ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

TRAIL induced apoptosis for cancer stem cells

Prof Waleed Arafat - Alexandria Faculty of Medicine, Alexandria, Egypt

TRAIL induced apoptosis for cancer stem cells ( Prof Waleed Arafat - Alexandria Faculty of Medicine, Alexandria, Egypt )

Carcinoid syndrome

Dr Rachel Riechelmann - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil

Carcinoid syndrome ( Dr Rachel Riechelmann - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil )

Who should receive combination therapy for ER positive breast cancer?

Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

Who should receive combination therapy for ER positive breast cancer? ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )

Positive lessons of negative trials

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Positive lessons of negative trials ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

Drug repurposing of propranolol

Dr Pan Pantziarka - Anticancer Fund, UK

Drug repurposing of propranolol ( Dr Pan Pantziarka - Anticancer Fund, UK )

ESMO 2016 conference highlights

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody:

Dr Omid Hamid - The Angeles Clinic, California, USA

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: ( Dr Omid Hamid - The Angeles Clinic, California, USA )

LUME study of nintedanib finds improved PFS, but no overall survival boost

Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium

LUME study of nintedanib finds improved PFS, but no overall survival boost ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )

Left versus right sided GI tumour response in the CRYSTAL trial

Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium

Left versus right sided GI tumour response in the CRYSTAL trial ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )

Looking for new pathways in colorectal cancer

Prof Nils Brünner - Copenhagen University, Copenhagen, Denmark

Looking for new pathways in colorectal cancer ( Prof Nils Brünner - Copenhagen University, Copenhagen, Denmark )

Caring for lung cancer patients

Dr Mark Doherty - Princess Margaret Hospital, Toronto, Canada

Caring for lung cancer patients ( Dr Mark Doherty - Princess Margaret Hospital, Toronto, Canada )

Oncolytic virotherapy using coxsackie virus

Dr Hardev Pandha - University of Surrey, Guildford, UK

Oncolytic virotherapy using coxsackie virus ( Dr Hardev Pandha - University of Surrey, Guildford, UK )

Results of the Activ8 trial of novel immunotherapy motolimod

Dr Ezra Cohen - UC San Diego, San Diego, USA

Results of the Activ8 trial of novel immunotherapy motolimod ( Dr Ezra Cohen - UC San Diego, San Diego, USA )

Lurbinectedin in PARP resistant breast cancer

Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Lurbinectedin in PARP resistant breast cancer ( Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry

Dr Simon Chowdhury - Guy's Hospital, London, UK

Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry ( Dr Simon Chowdhury - Guy's Hospital, London, UK )

Lurbinectedin in BRCA 1/2 breast cancer

Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Lurbinectedin in BRCA 1/2 breast cancer ( Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Olaparib and paclitaxel for 2nd line gastric cancer therapy

Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea

Olaparib and paclitaxel for 2nd line gastric cancer therapy ( Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea )

Innovative uses of kinase inhibitors in cancer

Dr Jordi Rodón - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Innovative uses of kinase inhibitors in cancer ( Dr Jordi Rodón - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Comment: Ipilimumab in high risk stage III melanoma

Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium

Comment: Ipilimumab in high risk stage III melanoma ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )

Comment: Niraparib for ovarian cancer

Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium

Comment: Niraparib for ovarian cancer ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )

Comment: Ribociclib for breast cancer

Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium

Comment: Ribociclib for breast cancer ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )

Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate

Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA

Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate ( Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA )

Highlights of ESMO 2016

Dr Andrés Cervantes - ESMO 2016 Scientific Chair

Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )

Adjuvant sunitinib for renal cell carcinoma

Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Adjuvant sunitinib for renal cell carcinoma ( Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France )

Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer

Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer ( Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France )

Custirsen shows no survival benefit in metastatic prostate cancer

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Custirsen shows no survival benefit in metastatic prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Benefits of adjuvant chemo for soft tissue sarcoma patients

Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy

Benefits of adjuvant chemo for soft tissue sarcoma patients ( Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy )

Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma

Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy

Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma ( Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy )

Cabozantinib over sunitinib for metastatic renal cell carcinoma

Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA

Cabozantinib over sunitinib for metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )

Promising results in metastatic bladder cancer using immunotherapy

Dr Matthew Galsky - Mount Sinai, New York, USA

Promising results in metastatic bladder cancer using immunotherapy ( Dr Matthew Galsky - Mount Sinai, New York, USA )

Negative trial results of custirsen for metastatic prostate cancer

Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France

Negative trial results of custirsen for metastatic prostate cancer ( Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France )

Cabozantinib improves PFS in metastatic renal cell carcinoma

Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA

Cabozantinib improves PFS in metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )

Advances for NSCLC in review

Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland

Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )

Ceritinib following crizotinib relapse for ALK positive NSCLC

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )

Atezolizumab v docetaxel for NSCLC: results from the OAK trial

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )

Significant survival gains with atezolizumab for NSCLC

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )

Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

Pembrolizumab plus chemo as firstline therapy for NSCLC

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

Firstline pembrolizumab plus chemo improves NSCLC outcomes

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Firstline pembrolizumab plus chemo improves NSCLC outcomes ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )

KRAS in the clinic and conference

Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)

Dr Arndt Stahler - University of Munich, Munich, Germany

A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1) ( Dr Arndt Stahler - University of Munich, Munich, Germany )

Thousands of melanoma patients in Europe have no access to new drugs

Prof Lidija Kandolf Sekulovic - Military Medical Academy, Belgrade, Serbia

Thousands of melanoma patients in Europe have no access to new drugs ( Prof Lidija Kandolf Sekulovic - Military Medical Academy, Belgrade, Serbia )

Phase I results of a novel FGFR inhibitor

Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland

Phase I results of a novel FGFR inhibitor ( Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland )

Firstline pembrolizumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Firstline pembrolizumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Adjuvant immunotherapy improves melanoma outcomes

Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France

Adjuvant immunotherapy improves melanoma outcomes ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )

Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer

Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France

Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer ( Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France )

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer

Prof John Robertson - University of Nottingham, Nottingham, UK

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer ( Prof John Robertson - University of Nottingham, Nottingham, UK )

Fulvestrant in FALCON trial improves PFS in advanced breast cancer

Dr Matthew Ellis - Washington University in St Louis, USA

Fulvestrant in FALCON trial improves PFS in advanced breast cancer ( Dr Matthew Ellis - Washington University in St Louis, USA )

Dabrafenib shows higher response and lower toxicity in paediatric brain cancer trial

Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA

Dabrafenib shows higher response and lower toxicity in paediatric brain cancer trial ( Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA )

Ribociclib improves progression-free survival in advanced breast cancer

Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US

Ribociclib improves progression-free survival in advanced breast cancer ( Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US )

Outcome of ovarian cancer patients was significantly improved with niraparib

Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark

Outcome of ovarian cancer patients was significantly improved with niraparib ( Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark )

Niraparib significantly improves outcomes for ovarian cancer patients

Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark

Niraparib significantly improves outcomes for ovarian cancer patients ( Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark )

Ipilimumab as adjuvant therapy improves OS in high risk melanoma

Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France

Ipilimumab as adjuvant therapy improves OS in high risk melanoma ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )

Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer

Dr Gabriel Hortobagyi - MD Anderson, Houston, USA

Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer ( Dr Gabriel Hortobagyi - MD Anderson, Houston, USA )

More from ecancer